PHOX2B PC-CAR T Cells

Phase 1Cell therapy

SStephan Grupp MD PhD

PHOX2B PC-CAR T Cells is one of 2 biologic programs targeting Refractory Neuroblastoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Refractory NeuroblastomaActive, not recruiting

Refractory NeuroblastomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Refractory Neuroblastoma

#DrugCompanyPhaseTrials

GPC2 CAR T Cells

SStanford University

Phase 1

1 2

PHOX2B PC-CAR T Cells

SStephan Grupp MD PhD

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2035

Phase 1Active, not recruiting

Refractory Neuroblastoma

NCT07007117

Clinical

Trials by Indication[1]

Refractory Neuroblastoma1 trial

Phase 1 Trial of PHOX2B Peptide-Centric Chimeric Antigen Receptor Autologous T Cells (PHOX2B PC-CAR T) for Relapsed Neuroblastoma

Active, not recruiting·SStephan Grupp MD PhD·Phase 1·NCT07007117·38 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for PHOX2B PC-CAR T Cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PHOX2B PC-CAR T Cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PHOX2B PC-CAR T Cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Stephan Grupp MD PhD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: SStephan Grupp MD PhD

PHOX2B PC-CAR T Cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2035

Trials by Indication[1]

Refractory Neuroblastoma1 trial

References

Drug Info

Quick Facts

Related News